N/A N=50 Maintaining Cognitive Health in Aging Veterans
Healthy People Programs
Primary: Knowledge of Memory Aging Questionnaire-Revised — 19.8; 19.5 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 Contrast ICE for Myocardial Scar in VT Ablations
Ventricular Tachycardia · Ischemic Cardiomyopathy
Primary: Number of Subjects With Myocardial Scar on Echo and Voltage Maps — 20 Participants
N/A N=958 Gestational Diabetes Mellitus Trial (GDM)
Diabetes, Gestational
Primary: Number of Participants With Composite Neonatal Morbidity — 149; 163; 62; 55 Participants — p=0.14
Phase 4 N=60 Geriatric Ketamine for Pain Management Study
Pain
Primary: Reduction of Pain Score at 30 Minutes — 4.4; 4.2 score on a scale
N/A N=98 Development & Testing of a Decision Aid for LVAD Placement
End-Stage Heart Failure · Bridge-to-Transplant LVAD Placement (BTT) · Destination Therapy LVAD Placement (DT)
Primary: Left Ventricular Assist Device (LVAD) Knowledge Scale — 45.6; 43.8 units on a scale
Phase 4 N=69 Long Term Effectiveness of Trigger Finger Injections With Triamcinolone vs. Dexamethasone
Trigger Finger Disorder
Primary: Number of Participants With no Symptoms of Trigger Finger — 28; 9 Participants
N/A N=22 NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test
Allergy Skin · Allergy · Dermatitis, Allergic Contact
Primary: Wheal Formation — .85; 6.68; .2 mm
N/A N=300 Evaluation of Factors Associated With Patient Satisfaction and Mood-State in Regional Anesthesia
Outcome Assessment · Patient Satisfaction
Primary: Overall Patient Satisfaction — 247; 53 Participants
Phase 4 N=351 Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis
Type 2 Diabetes Mellitus · Coronary Atherosclerosis
Primary: Prevalence of Occult Myocardial Scar on Delayed-enhanced MRI in Asymptomatic Patients With Type 2 Diabetes Mellitus — 23 Participants
Phase 3 N=10 Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye
Diabetic Macular Edema
Primary: Maximum Concentration (Cmax) of Anti-VEGF Antibody — 25.22; 9.56 ng/mL
Phase 1 N=58 Study of MLN8237 in Participants With Advanced Hematological Malignancies
B-cell Follicular Lymphoma · B-cell Marginal Zone Lymphoma · Diffuse Large B-cell Lymphoma
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 1; 2; 0; 1 participants
Phase 4 N=275 Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
Renal Transplant Rejection
Primary: Incidence of Acute Cellular Rejection — 7; 31 Participants
Phase 3 N=16 Study of Botulinum Toxin and Recovery of Hand Function After Stroke
Stroke With Hemiparesis
Primary: Time Taken to Form a Stable Grasp Pre-Treatment — 1.51; 1.14 Preload phase duration in Seconds
Phase 3 N=106 Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Primary: Number of Participants Having Reached the Composite Efficacy Endpoint of Biopsy-proven Acute Rejection — 5; 3; 5; 5 Participants — p=0.9712
N/A N=56 Use of Non-Invasive Positive Pressure Ventilation in Patients With Severe Obesity Undergoing Upper Endoscopy Procedures
Severe Obesity · Hypoxia
Primary: Percentage of Participants With an Oxygen Desaturation Event ≤ 94% — 57.1; 14.3 percentage of participants